Sensei Biotherapeutics (NASDAQ:FTH) Stock Price Down 6.3% - Here's What Happened

Key Points

• Sensei Biotherapeutics shares fell 6.3% to about $27.87, with trading volume below its daily average.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $56.25, substantially above the current share price.
• The clinical-stage cancer-immunotherapy company beat quarterly EPS expectations, reporting a loss of $2.84 per share versus the anticipated $5.04 loss; institutional investors own 10.5% of its stock.

Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report) was down 6.3% during trading on Thursday. The stock traded as low as $27.77 and last traded at $27.8650. Approximately 161,127 shares were traded during mid-day trading, a decline of 32% from the average daily volume of 238,595 shares. The stock had previously closed at $29.74.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on FTH shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Oppenheimer began coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They issued an "outperform" rating and a $60.00 target price on the stock. JonesTrading assumed coverage on Sensei Biotherapeutics in a research report on Tuesday, August 4th. They set a "buy" rating and a $55.00 price target for the company. TD Cowen initiated coverage on Sensei Biotherapeutics in a research note on Wednesday, September 9th. They issued a "buy" rating for the company. Finally, Raymond James Financial assumed coverage on Sensei Biotherapeutics in a report on Friday, July 31st. They set an "outperform" rating and a $56.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $56.25.

Sensei Biotherapeutics Stock Performance

The stock's 50 day moving average price is $32.08. The stock has a market capitalization of $721.48 million, a price-to-earnings ratio of -0.20 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping the consensus estimate of ($5.04) by $2.20. On average, equities analysts predict that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current year.

Hedge Funds Weigh In On Sensei Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of FTH. Citadel Advisors LLC purchased a new stake in shares of Sensei Biotherapeutics in the second quarter valued at $307,000. Alyeska Investment Group L.P. purchased a new stake in Sensei Biotherapeutics in the 2nd quarter worth about $3,610,000. Vivo Capital LLC acquired a new stake in Sensei Biotherapeutics during the 1st quarter worth about $22,758,000. Bank of America Corp DE grew its stake in Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock valued at $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Finally, Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $4,188,000. Institutional investors and hedge funds own 10.50% of the company's stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company's research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei's technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.